CDT Equity Inc. (CDT): auditor change — Conduit Pharmaceuticals changes auditor from Marcum to CBIZ CPAs; going concern and material weaknesses cited

CDT Equity Inc.

Marcum LLP resigned as independent auditor on April 24, 2025; CBIZ CPAs P.C. appointed on April 25, 2025.
Audit reports for FYE 2024 and 2023 included a going concern explanatory paragraph due to substantial doubt.
Material weaknesses in internal controls identified: inadequate segregation of duties, lack of review controls, restatement.
No accounting disagreements between Company and Marcum; no reportable events except the material weaknesses noted.

item 4.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Auditor Changes SEC 8-K Item 4.01/4.02 confidence 0.9

CDT Equity Inc. engaged CBIZ CPAs P.C. as its auditor.

Action: engagement
Auditor: CBIZ CPAs P.C.

Exact text from the filing

On April 25, 2025, with the approval of the Audit Committee of the Company’s Board of Directors (the “Board”), CBIZ CPAs was engaged as the Company’s independent registered public accounting firm.

View on SEC.gov

Auditor Changes SEC 8-K Item 4.01/4.02 confidence 0.9

Marcum LLP resigned as auditor of CDT Equity Inc..

Action: resignation
Auditor: Marcum LLP
Successor: CBIZ CPAs P.C.

Exact text from the filing

On April 24, 2025, Conduit Pharmaceuticals Inc. (the “Company”) was notified by Marcum LLP (“Marcum”) that Marcum resigned as the Company’s independent registered public accounting firm.

View on SEC.gov

8 auditor changes filed in the last 30 days. Browse all auditor changes →

CDT Equity Inc. filing history →

Source: SEC EDGAR

accession 0001641172-25-006224

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.